Drugmakers pledge shorter launch times for drugs in EU

Pharmaceutical companies have said they will try to carve months off the time between approval and launch for new medicines in Europe, and reduce disparities in access between countries.

China's insulin plans will hit 2022 revenues, says Novo Nord...

Novo Nordisk has said that the introduction of value-based procurement (VBP) for insulin products by the Chinese government will have an impact on its revenues next year.

ICER methods could be illegal in US, claims US think tank

Demonstrating value – the future for market access

With the US joining other countries around the world in demanding definitions and measurements of the value of treatments, the pharma industry faces the challenge of understanding the requireme

Realising the true potential of health wearables

The age of digital and wearables is upon us - but how can we realise its full potential?